Navigation Links
Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Date:10/5/2007

- Presentation to highlight milestones including phase III development of

'GI-friendly' NSAIDs for mild to moderate pain -

PALO ALTO, Calif., Oct. 5 /PRNewswire/ --

What: Horizon Therapeutics, Inc. is pleased to announce that

George Tidmarsh, M.D., Ph.D., chief executive officer, will

showcase Horizon's corporate and clinical milestones,

including its recent completion of Series C financing, and

provide an update on the development of the Company's

product pipeline during an Open House Podium Presentation

at BioPartnering Europe (BPE). Immediately following the

presentation Dr. Tidmarsh will be available to field

questions and provide more detailed information on Horizon

Therapeutics.

BPE was first held in London in 1993 as a partnership

between the U.S. Commercial Service and Technology Vision

Group LLC to bring about closer ties between American and

European biotechnology companies. From the beginning, BPE

has attracted the support of leading pharmaceutical,

biotechnology, financial and service companies that have

all contributed to making BPE one of the leading

independent partnering events in the world. BPE has a high

rate of sponsor retention, which indicates its prominent

position on the annual conference calendar for many

industry leaders.

When: Monday, October 8, 2007

9:30 a.m. - 12:45 p.m. Open House Podium Presentation

(10:45-10:55 a.m. Horizon presentation)

Where: London, England

QEII Conference Centre

Abbey Room West - Stream 1

Spokespeople: George Tidmarsh, M.D., Ph.D., co-founder and CEO of Horizon

Therapeutics

Barry Golombik, co-founder of Horizon Therapeutics

Contact: Julie Normart

WeissComm Partners

415.946.1087

jnormart@weisscommpartners.com

About Horizon Therapeutics:

Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, entered Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combination products in earlier stages of development. For more information visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New hope on the Horizon for People Wishing to Quit Smoking
2. A new horizon
3. Conjoined Indian Twins See Hope On The Horizon
4. Stem cell cure for peripheral vascular disease: New hope on the horizon
5. Oral Flu Vaccine On The Horizon In Russia
6. Rescheduled: Aerial Mosquito Treatment for Philadelphia
7. First Keyhole Heart Valve Surgery Scheduled in Britain
8. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
9. Researchers Present Ways To Reduce The Risk Of Dementia
10. Researchers Present Data Regarding The Efficiency Of Herbs
11. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... Multiple award ... been family-owned and operated for over 35 years. Maintaining core values of exceptional customer ... their success and made them a leading name in San Diego plumbing, and other ...
(Date:5/6/2016)... ... May 06, 2016 , ... In honor ... education and corporate training, and the National Military Family Association, a nonprofit that ... as the second full-tuition scholarship recipient of 2016. , “Being awarded this ...
(Date:5/6/2016)... ... 2016 , ... “ Crossing Over: Affirmations of Faith in the Midst of ... allowed those holding vigil to glimpse into the supernatural as their lives ended. With ... spiritually and practically gain insight into providing care to terminal patients. , “I ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession ... the impact our aging population has on communities and resources. Aging Life Care plays ... and face age-related challenges. , Aging Life Care is a holistic, client-centered approach ...
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is excited ... for public stakeholder review. The stakeholder review is an important opportunity for interested parties ... and delivers value to the wool industry., The RWS is intended to be a ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016  Compass Diversified Holdings (NYSE: ... owner of leading middle market businesses, announced today its ... 31, 2016. First Quarter 2016 Highlights ... ("CAD" or "Cash Flow") of $13.6 million for the ... of $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... Yissum Research Development Company ... that it had signed an exclusive world-wide licensing and ... novel protein degradation and immunomodulatory drugs for cancer and ... candidates representing first-in-class therapy for hematologic and solid malignancies. ... The novel technology was developed by Yinon ...
(Date:5/4/2016)... 2016 Research and ... Acute Myeloid Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia ...
Breaking Medicine Technology: